INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2016. The put-call ratio across all filers is 0.81 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,208,753 | +445.0% | 134,454 | +450.6% | 0.06% | +436.4% |
| Q1 2024 | $1,689,725 | -85.8% | 24,418 | -85.3% | 0.01% | -86.1% |
| Q4 2023 | $11,897,586 | +696.9% | 166,121 | +418.0% | 0.08% | +558.3% |
| Q3 2022 | $1,493,000 | -58.6% | 32,071 | -49.3% | 0.01% | -65.7% |
| Q2 2022 | $3,608,000 | -39.8% | 63,201 | -35.5% | 0.04% | -35.2% |
| Q1 2022 | $5,992,000 | +427.0% | 97,925 | +351.0% | 0.05% | +440.0% |
| Q4 2021 | $1,137,000 | -45.4% | 21,715 | -83.5% | 0.01% | -94.7% |
| Q3 2017 | $2,083,000 | +313.3% | 131,980 | +325.9% | 0.19% | +272.5% |
| Q1 2017 | $504,000 | +9.6% | 30,989 | +161.0% | 0.05% | -50.5% |
| Q2 2016 | $460,000 | – | 11,871 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
| Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
| Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
| WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
| SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
| Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
| EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
| Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |